An FDA advisory committee overwhelmingly panned the idea that Purdue Pharma’s abuse-deterrent formulation (ADF) of oxycodone (OxyContin) “meaningfully reduced” overall opioid abuse, overdose and death.
Posted 10/23/20
An FDA advisory committee overwhelmingly panned the idea that Purdue Pharma’s abuse-deterrent formulation (ADF) of oxycodone (OxyContin) “meaningfully reduced” overall opioid abuse, overdose and death.